{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:44:08Z","timestamp":1790905448973,"version":"4.1.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,6,9]],"date-time":"2010-06-09T00:00:00Z","timestamp":1276041600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10157-010-0298-8","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T05:54:24Z","timestamp":1275976464000},"page":"303-314","source":"Crossref","is-referenced-by-count":37,"title":["Activation of the aldosterone\/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome"],"prefix":"10.1007","volume":"14","author":[{"given":"Miki","family":"Nagase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,9]]},"reference":[{"key":"298_CR1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","volume":"237","author":"JL Arriza","year":"1987","unstructured":"Arriza JL, Weinberger C, Cerelli G, et\u00a0al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268\u201375.","journal-title":"Science"},{"key":"298_CR2","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","volume":"119","author":"M Epstein","year":"2006","unstructured":"Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912\u20139.","journal-title":"Am J Med"},{"key":"298_CR3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","volume":"14","author":"TH Hostetter","year":"2003","unstructured":"Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003;14:2395\u2013401.","journal-title":"J Am Soc Nephrol"},{"key":"298_CR4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"KT Weber","year":"2001","unstructured":"Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689\u201397.","journal-title":"N Engl J Med"},{"key":"298_CR5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, et\u00a0al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33\u201341.","journal-title":"N Engl J Med"},{"key":"298_CR6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.107.708537","volume":"116","author":"E Ingelsson","year":"2007","unstructured":"Ingelsson E, Pencina MJ, Tofler GH, et\u00a0al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984\u201392.","journal-title":"Circulation"},{"key":"298_CR7","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G Guder","year":"2007","unstructured":"Guder G, Bauersachs J, Frantz S, et\u00a0al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754\u201361.","journal-title":"Circulation"},{"key":"298_CR8","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","volume":"114","author":"F Beygui","year":"2006","unstructured":"Beygui F, Collet JP, Benoliel JJ, et\u00a0al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114:2604\u201310.","journal-title":"Circulation"},{"key":"298_CR9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","volume":"21","author":"RJ Hene","year":"1982","unstructured":"Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982;21:98\u2013101.","journal-title":"Kidney Int"},{"key":"298_CR10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","volume":"112","author":"M Quinkler","year":"2005","unstructured":"Quinkler M, Zehnder D, Eardley KS, et\u00a0al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005;112:1435\u201343.","journal-title":"Circulation"},{"key":"298_CR11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","volume":"49","author":"S Shibata","year":"2007","unstructured":"Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49:355\u201364.","journal-title":"Hypertension"},{"key":"298_CR12","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1681\/ASN.2006080944","volume":"17","author":"M Nagase","year":"2006","unstructured":"Nagase M, Yoshida S, Shibata S, et\u00a0al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438\u201346.","journal-title":"J Am Soc Nephrol"},{"key":"298_CR13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata S, Nagase M, Yoshida S, et\u00a0al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370\u20136.","journal-title":"Nat Med"},{"key":"298_CR14","first-page":"19","volume":"36","author":"H Selye","year":"1943","unstructured":"Selye H, Hall C. Pathologic changes induced in various species by overdosage with desoxycorticosterone. Arch Pathol. 1943;36:19\u201331.","journal-title":"Arch Pathol"},{"key":"298_CR15","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"CG Brilla","year":"1990","unstructured":"Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355\u201364.","journal-title":"Circ Res"},{"key":"298_CR16","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","volume":"93","author":"M Young","year":"1994","unstructured":"Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578\u201383.","journal-title":"J Clin Invest"},{"key":"298_CR17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et\u00a0al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"298_CR18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et\u00a0al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"298_CR19","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et\u00a0al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831\u20138.","journal-title":"Circulation"},{"key":"298_CR20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","volume":"93","author":"GH Williams","year":"2004","unstructured":"Williams GH, Burgess E, Kolloch RE, et\u00a0al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004;93:990\u20136.","journal-title":"Am J Cardiol"},{"key":"298_CR21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","volume":"242","author":"JW Funder","year":"1988","unstructured":"Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583\u20135.","journal-title":"Science"},{"key":"298_CR22","first-page":"877","volume":"87","author":"S Kataoka","year":"2002","unstructured":"Kataoka S, Kudo A, Hirano H, et\u00a0al. 11beta-hydroxysteroid dehydrogenase type\u00a02 is expressed in the human kidney glomerulus. J Clin Endocrinol Metab. 2002;87:877\u201382.","journal-title":"J Clin Endocrinol Metab"},{"key":"298_CR23","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1681\/ASN.2005020129","volume":"16","author":"Y Terada","year":"2005","unstructured":"Terada Y, Kobayashi T, Kuwana H, et\u00a0al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase\u00a01\/2, cyclin D1, and cyclin A. J Am Soc Nephrol. 2005;16:2296\u2013305.","journal-title":"J Am Soc Nephrol"},{"key":"298_CR24","doi-asserted-by":"crossref","first-page":"E272","DOI":"10.1152\/ajpendo.00409.2002","volume":"285","author":"EP Gomez-Sanchez","year":"2003","unstructured":"Gomez-Sanchez EP, Ganjam V, Chen YJ, et\u00a0al. Regulation of 11 beta-hydroxysteroid dehydrogenase enzymes in the rat kidney by estradiol. Am J Physiol Endocrinol Metab. 2003;285:E272\u20139.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"298_CR25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456\u201362.","journal-title":"N Engl J Med"},{"key":"298_CR26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, et\u00a0al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939\u201345.","journal-title":"N Engl J Med"},{"key":"298_CR27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, et\u00a0al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73\u201387.","journal-title":"Ann Intern Med"},{"key":"298_CR28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et\u00a0al. Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"298_CR29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et\u00a0al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type\u00a02 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"298_CR30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, et\u00a0al. The effect of irbesartan on the development of diabetic nephropathy in patients with type\u00a02 diabetes. N Engl J Med. 2001;345:870\u20138.","journal-title":"N Engl J Med"},{"key":"298_CR31","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063\u20138.","journal-title":"J Clin Invest"},{"key":"298_CR32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ki.1992.45","volume":"41","author":"ZY Quan","year":"1992","unstructured":"Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 1992;41:326\u201333.","journal-title":"Kidney Int"},{"key":"298_CR33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999;33:232\u20137.","journal-title":"Hypertension"},{"key":"298_CR34","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1097\/01.ASN.0000078960.15147.05","volume":"14","author":"PN Chander","year":"2003","unstructured":"Chander PN, Rocha R, Ranaudo J, et\u00a0al. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol. 2003;14:1990\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"298_CR35","first-page":"F286","volume":"264","author":"M Horiuchi","year":"1993","unstructured":"Horiuchi M, Nishiyama H, Hama J, et\u00a0al. Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol. 1993;264:F286\u201391.","journal-title":"Am J Physiol"},{"key":"298_CR36","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","volume":"75","author":"WB Lea","year":"2009","unstructured":"Lea WB, Kwak ES, Luther JM, et\u00a0al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 2009;75:936\u201344.","journal-title":"Kidney Int"},{"key":"298_CR37","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","volume":"111","author":"A Fiebeler","year":"2005","unstructured":"Fiebeler A, Nussberger J, Shagdarsuren E, et\u00a0al. Aldosterone synthase inhibitor ameliorates angiotensin\u00a0II-induced organ damage. Circulation. 2005;111:3087\u201394.","journal-title":"Circulation"},{"key":"298_CR38","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, et\u00a0al. Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791\u2013800.","journal-title":"Kidney Int"},{"key":"298_CR39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00230355","volume":"425","author":"M Kretzler","year":"1994","unstructured":"Kretzler M, Koeppen-Hagemann I, Kriz W. Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat. Virchows Arch. 1994;425:181\u201393.","journal-title":"Virchows Arch"},{"key":"298_CR40","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00109-006-0082-0","volume":"84","author":"F Artunc","year":"2006","unstructured":"Artunc F, Amann K, Nasir O, et\u00a0al. Blunted DOCA\/high salt induced albuminuria and renal tubulointerstitial damage in gene-targeted mice lacking SGK1. J Mol Med. 2006;84:737\u201346.","journal-title":"J Mol Med"},{"key":"298_CR41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","volume":"107","author":"JW Conn","year":"1964","unstructured":"Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107:159\u201372.","journal-title":"Am J Surg"},{"key":"298_CR42","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","volume":"16","author":"J Ribstein","year":"2005","unstructured":"Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005;16:1320\u20135.","journal-title":"J Am Soc Nephrol"},{"key":"298_CR43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Desideri G, et\u00a0al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232\u20138.","journal-title":"Hypertension"},{"key":"298_CR44","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"298_CR45","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:542\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"key":"298_CR46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486\u201392.","journal-title":"Nat Clin Pract Nephrol"},{"key":"298_CR47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","volume":"91","author":"J Staessen","year":"1981","unstructured":"Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin\u00a0II suppression. J Endocrinol. 1981;91:457\u201365.","journal-title":"J Endocrinol"},{"key":"298_CR48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64\u20138.","journal-title":"Hypertension"},{"key":"298_CR49","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116\u201323.","journal-title":"Kidney Int"},{"key":"298_CR50","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMra052131","volume":"354","author":"K Tryggvason","year":"2006","unstructured":"Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med. 2006;354:1387\u2013401.","journal-title":"N Engl J Med"},{"key":"298_CR51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00020.2002","volume":"83","author":"H Pavenstadt","year":"2003","unstructured":"Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83:253\u2013307.","journal-title":"Physiol Rev"},{"key":"298_CR52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1172\/JCI119163","volume":"99","author":"ME Pagtalunan","year":"1997","unstructured":"Pagtalunan ME, Miller PL, Jumping-Eagle S, et\u00a0al. Podocyte loss and progressive glomerular injury in type\u00a0II diabetes. J Clin Invest. 1997;99:342\u20138.","journal-title":"J Clin Invest"},{"key":"298_CR53","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/diabetes.54.6.1626","volume":"54","author":"G Wolf","year":"2005","unstructured":"Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005;54:1626\u201334.","journal-title":"Diabetes"},{"key":"298_CR54","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","volume":"47","author":"M Nagase","year":"2006","unstructured":"Nagase M, Shibata S, Yoshida S, et\u00a0al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47:1084\u201393.","journal-title":"Hypertension"},{"key":"298_CR55","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1053\/j.ajkd.2006.07.025","volume":"48","author":"HM Chen","year":"2006","unstructured":"Chen HM, Liu ZH, Zeng CH, et\u00a0al. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis. 2006;48:772\u20139.","journal-title":"Am J Kidney Dis"},{"key":"298_CR56","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/01.HYP.0000145180.38707.84","volume":"44","author":"AK Bidani","year":"2004","unstructured":"Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44:595\u2013601.","journal-title":"Hypertension"},{"key":"298_CR57","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1172\/JCI111349","volume":"73","author":"LD Dworkin","year":"1984","unstructured":"Dworkin LD, Hostetter TH, Rennke HG, Brenner BM. Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. J Clin Invest. 1984;73:1448\u201361.","journal-title":"J Clin Invest"},{"key":"298_CR58","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1096\/fj.02-0125fje","volume":"16","author":"N Endlich","year":"2002","unstructured":"Endlich N, Sunohara M, Nietfeld W, et\u00a0al. Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J. 2002;16:1850\u20132.","journal-title":"FASEB J"},{"key":"298_CR59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1523-1755.2004.00362.x","volume":"65","author":"RV Durvasula","year":"2004","unstructured":"Durvasula RV, Petermann AT, Hiromura K, et\u00a0al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004;65:30\u20139.","journal-title":"Kidney Int"},{"key":"298_CR60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-140-3-200402030-00007","volume":"140","author":"J Chen","year":"2004","unstructured":"Chen J, Muntner P, Hamm LL, et\u00a0al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167\u201374.","journal-title":"Ann Intern Med"},{"key":"298_CR61","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1681\/ASN.2005010106","volume":"16","author":"M Kurella","year":"2005","unstructured":"Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134\u201340.","journal-title":"J Am Soc Nephrol"},{"key":"298_CR62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","volume":"48","author":"M Bochud","year":"2006","unstructured":"Bochud M, Nussberger J, Bovet P, et\u00a0al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239\u201345.","journal-title":"Hypertension"},{"key":"298_CR63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.HYP.0000253258.36141.c7","volume":"49","author":"S Kidambi","year":"2007","unstructured":"Kidambi S, Kotchen JM, Grim CE, et\u00a0al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007;49:704\u201311.","journal-title":"Hypertension"},{"key":"298_CR64","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.amjhyper.2006.07.012","volume":"20","author":"P Russo","year":"2007","unstructured":"Russo P, Lauria F, Loguercio M, et\u00a0al. 344C\/T Variant in the promoter of the aldosterone synthase gene (CYP11B2) is associated with metabolic syndrome in men. Am J Hypertens. 2007;20:218\u201322.","journal-title":"Am J Hypertens"},{"key":"298_CR65","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, et\u00a0al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"298_CR66","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.HYP.0000116223.97436.e5","volume":"43","author":"TL Goodfriend","year":"2004","unstructured":"Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43:518\u201324.","journal-title":"Hypertension"},{"key":"298_CR67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1161\/01.HYP.0000113294.06704.64","volume":"43","author":"TL Goodfriend","year":"2004","unstructured":"Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358\u201363.","journal-title":"Hypertension"},{"key":"298_CR68","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.2336140100","volume":"100","author":"M Ehrhart-Bornstein","year":"2003","unstructured":"Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et\u00a0al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"298_CR69","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","volume":"147","author":"C Guo","year":"2006","unstructured":"Guo C, Martinez-Vasquez D, Mendez GP, et\u00a0al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006;147:5363\u201373.","journal-title":"Endocrinology"},{"key":"298_CR70","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1681\/ASN.V10122488","volume":"10","author":"JM Kumar","year":"1999","unstructured":"Kumar JM, Brooks DP, Olson BA, Laping NJ. Sgk, a putative serine\/threonine kinase, is differentially expressed in the kidney of diabetic mice and humans. J Am Soc Nephrol. 1999;10:2488\u201394.","journal-title":"J Am Soc Nephrol"},{"key":"298_CR71","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1016\/j.febslet.2006.06.034","volume":"580","author":"KY Kim","year":"2006","unstructured":"Kim KY, Kim HY, Kim JH, et\u00a0al. Tumor necrosis factor-alpha and interleukin-1beta increases CTRP1 expression in adipose tissue. FEBS Lett. 2006;580:3953\u201360.","journal-title":"FEBS Lett"},{"key":"298_CR72","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1096\/fj.07-9412com","volume":"22","author":"JH Jeon","year":"2008","unstructured":"Jeon JH, Kim KY, Kim JH, et\u00a0al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 2008;22:1502\u201311.","journal-title":"FASEB J"},{"key":"298_CR73","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2796.2004.01390.x","volume":"256","author":"JC Verhave","year":"2004","unstructured":"Verhave JC, Hillege HL, Burgerhof JG, et\u00a0al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med. 2004;256:324\u201330.","journal-title":"J Intern Med"},{"key":"298_CR74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/HYPERTENSIONAHA.108.111815","volume":"52","author":"H Matsui","year":"2008","unstructured":"Matsui H, Ando K, Kawarazaki H, et\u00a0al. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension. 2008;52:287\u201394.","journal-title":"Hypertension"},{"key":"298_CR75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.1123348","volume":"312","author":"JT Bridgham","year":"2006","unstructured":"Bridgham JT, Carroll SM, Thornton JW. Evolution of hormone-receptor complexity by molecular exploitation. Science. 2006;312:97\u2013101.","journal-title":"Science"},{"key":"298_CR76","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.HYP.0000203772.78696.67","volume":"47","author":"K Nagata","year":"2006","unstructured":"Nagata K, Obata K, Xu J, et\u00a0al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656\u201364.","journal-title":"Hypertension"},{"key":"298_CR77","doi-asserted-by":"crossref","first-page":"38911","DOI":"10.1074\/jbc.M103984200","volume":"276","author":"D Le Menuet","year":"2001","unstructured":"Le Menuet D, Isnard R, Bichara M, et\u00a0al. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem. 2001;276:38911\u201320.","journal-title":"J Biol Chem"},{"key":"298_CR78","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","volume":"111","author":"A Ouvrard-Pascaud","year":"2005","unstructured":"Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et\u00a0al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025\u201333.","journal-title":"Circulation"},{"key":"298_CR79","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.270.5241.1491","volume":"270","author":"S Kato","year":"1995","unstructured":"Kato S, Endoh H, Masuhiro Y, et\u00a0al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995;270:1491\u20134.","journal-title":"Science"},{"key":"298_CR80","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.283.5406.1317","volume":"283","author":"J Yanagisawa","year":"1999","unstructured":"Yanagisawa J, Yanagi Y, Masuhiro Y, et\u00a0al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science. 1999;283:1317\u201321.","journal-title":"Science"},{"key":"298_CR81","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1074\/jbc.M005547200","volume":"276","author":"LF Su","year":"2001","unstructured":"Su LF, Knoblauch R, Garabedian MJ. Rho GTPases as modulators of the estrogen receptor transcriptional response. J Biol Chem. 2001;276:3231\u20137.","journal-title":"J Biol Chem"},{"key":"298_CR82","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.1074\/jbc.M509339200","volume":"281","author":"T Kino","year":"2006","unstructured":"Kino T, Souvatzoglou E, Charmandari E, et\u00a0al. Rho family Guanine nucleotide exchange factor Brx couples extracellular signals to the glucocorticoid signaling system. J Biol Chem. 2006;281:9118\u201326.","journal-title":"J Biol Chem"},{"key":"298_CR83","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1038\/sj.onc.1202921","volume":"18","author":"A Togawa","year":"1999","unstructured":"Togawa A, Miyoshi J, Ishizaki H, et\u00a0al. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene. 1999;18:5373\u201380.","journal-title":"Oncogene"},{"key":"298_CR84","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1073\/pnas.0307512101","volume":"101","author":"Y Gao","year":"2004","unstructured":"Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A. 2004;101:7618\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"298_CR85","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nm1274","volume":"11","author":"JA Cancelas","year":"2005","unstructured":"Cancelas JA, Lee AW, Prabhakar R, et\u00a0al. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat Med. 2005;11:886\u201391.","journal-title":"Nat Med"},{"key":"298_CR86","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1152\/physrev.2001.81.1.153","volume":"81","author":"Y Takai","year":"2001","unstructured":"Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81:153\u2013208.","journal-title":"Physiol Rev"},{"key":"298_CR87","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.cell.2008.01.052","volume":"133","author":"X Wu","year":"2008","unstructured":"Wu X, Tu X, Joeng KS, et\u00a0al. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008;133:340\u201353.","journal-title":"Cell"},{"key":"298_CR88","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1083\/jcb.200604073","volume":"175","author":"T Kawashima","year":"2006","unstructured":"Kawashima T, Bao YC, Nomura Y, et\u00a0al. Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors. J Cell Biol. 2006;175:937\u201346.","journal-title":"J Cell Biol"},{"key":"298_CR89","doi-asserted-by":"crossref","unstructured":"Ando K, Ohtsu H, Arakawa Y, et\u00a0al. Rationale and design of the eplerenone combination versus conventional agents to lower blood pressure on urinary antialbuminuric treatment effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res. 2010.","DOI":"10.1038\/hr.2010.46"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-010-0298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-010-0298-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-010-0298-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T02:15:17Z","timestamp":1635473717000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-010-0298-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,9]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1007\/s10157-010-0298-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,9]]}}}